Company

Company

What if we could change how drugs are developed?

The pharmaceutical industry uses a legacy point-to-point sub-optimized approach to drug discovery and development that is inefficient, expensive, and too often ends in failure.

Valo is harnessing and building Opal to identify and advance our supply chain of programs across cardiovascular-metabolic-renal, oncology, and neurodegenerative disease areas, including our three lead product candidates - two of which are expected to enter Phase 2 clinical trials in 2021 and 2022 respectively - and our 14 other discovery-stage programs.

About us

Founded by Flagship Pioneering, Valo is a mission-driven technology company that was created with the belief that the drug discovery and development process can and should be better—faster, less expensive, and with a higher probability of success.

Valo is using human-centric data and artificial intelligence-powered compute across the entire drug development lifecycle into a single unified architecture, with the aim to accelerate and transform the discovery and development of life-changing drugs while simultaneously reducing the cost, time, and failure rate.

Valo's Opal Computational Platform™, a fully integrated, closed loop, end-to-end drug development platform, offers a unique approach to therapeutic development that enables Valo to advance a robust pipeline of candidates across cardiovascular disease, oncology, and neurodegeneration.


Team

Setting the pace for future discovery.

Meet our team of preeminent leaders in science, technology, pharmaceuticals, and public policy, united to change the world.